Blog
About

5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial.

      Mycology

      Adenocarcinoma, drug therapy, secondary, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Bone Neoplasms, Double-Blind Method, Humans, Lymphatic Metastasis, Male, Middle Aged, Neoplasms, Hormone-Dependent, pathology, Placebos, Prednisone, administration & dosage, Prognosis, Prostatic Neoplasms, Quinazolines, Survival Rate, Treatment Outcome

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Abnormal epidermal growth factor receptor expression and pre-clinical data prompted us to investigate the activity of gefitinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor, in hormone-refractory prostate cancer. Eighty-two patients were randomly assigned to receive prednisone plus gefitinib (pG; n = 44) or prednisone plus placebo (ppl; n = 38). On progression, patients initially assigned to placebo were offered the possibility to receive gefitinib. Best prostate-specific antigen response was the primary endpoint. At a median follow-up time of 29.0 months (26.0-32.0), 77 patients progressed and 51 died. Prostate-specific antigen response was recorded in 6/38 (15.8%; 95% CI 4.2-27.4) and in 5/44 (11.4%; 95% CI 2.0-20.8) patients in pG and ppl groups, respectively. There was no difference between groups in time to progression (median pG 4.0 months, range 3.5-4.5; median ppl 4.5 months, range 3.5-5.0) and survival (median pG 26.5 months, range 16.0-37.0; median ppl 20.5 months, range 14.0-27.0). Adverse events occurred in 19 patients in each arm and were generally mild. pG showed a good tolerability profile but only a limited therapeutic activity in hormone-refractory prostate cancer. (c) 2008 S. Karger AG, Basel.

          Related collections

          Author and article information

          Journal
          18714171
          10.1159/000151391

          Comments

          Comment on this article